Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.48 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6661759 | 0.88 | KHK (0.47) | KHKTRPV4CYP11B1CYP11B2KDM4E | |
| SCHEMBL332547 | 0.83 | TRPV4 (0.56) | KHKTRPV4CYP11B1CYP11B2KDM4E | |
| SCHEMBL405495 | 0.82 | KHK (0.47) | KHKTRPV4CYP11B1CYP11B2GAA | |
| SCHEMBL12225106 | 0.82 | KHK (0.39) | KHKTRPV4CYP11B1CYP11B2KDM4E | |
| SCHEMBL406276 | 0.82 | KHK (0.43) | KHKTRPV4CYP11B1CYP11B2KDM4E | |
| SCHEMBL24816757 | 0.82 | KHK (0.43) | KHKTRPV4CYP11B1CYP11B2MEN1 | |
| SCHEMBL404670 | 0.82 | EGLN2 (0.39) | KHKTRPV4CYP11B1CYP11B2KDM4E | |
| SCHEMBL31339917 | 0.82 | KHK (0.43) | KHKTRPV4CYP11B1CYP11B2MEN1 | |
| SCHEMBL14358481 | 0.82 | KHK (0.52) | KHKTRPV4CYP11B1CYP11B2GAA | |
| SCHEMBL6630371 | 0.81 | KDM4E (0.43) | KHKTRPV4KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1003718-B1 | METHOD FOR THE PRODUCTION OF N-(5-AMINO-2-CYANO-4-FLUORO-PHENYL)-SULPHONAMIDES | BAYER CROPSCIENCE AG (DE) | 2004-04-28 | — | — | EP | claimed |
| US-6545154-B2 | Herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-08 | — | — | US | claimed |
| US-20030040626-A1 | Method for the production of N-(5-amino-2-cyano-4-fluoro-phenyl)-sulphonamides and new intermediate products | HUPPERTS ACHIM (DE) | 2003-02-27 | — | — | US | claimed |
| US-6310206-B1 | 2-AMINO-4,5-DIFLUORO-BENZONITRILE IS REACTED A SULPHONYL HALIDES; N-(2-CYANO-4,5-DIFLUORO-PHENYL)-SULPHONAMIDES (CLAIMED AS INTERMEDIATES) OBTAINED IN THE FIRST STEP ARE AMINATED WITH AMMONIA | BAYER AKTIENGESELLSCHAFT (DE) | 2001-10-30 | — | — | US | claimed |
| CN-1265095-A | Process for the preparation of N- (5-amino-2-cyano-4-fluorophenyl) sulfonamides and novel intermediates | BAYER AG (DE) | 2000-08-30 | — | — | CN | claimed |
| EP-1003718-A1 | METHOD FOR THE PRODUCTION OF N-(5-AMINO-2-CYANO-4-FLUORO-PHENYL)-SULPHONAMIDES AND NEW INTERMEDIATE PRODUCTS | BAYER AG (DE) | 2000-05-31 | — | — | EP | claimed |
| WO-1999005098-A1 | METHOD FOR THE PRODUCTION OF N-(5-AMINO-2-CYANO-4-FLUORO-PHENYL)-SULPHONAMIDES AND NEW INTERMEDIATE PRODUCTS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-02-04 | — | — | WO | claimed |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4594307-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| WO-2024073426-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023227080-A1 | PROTAC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 百极弘烨(南通)医药科技有限公司 | 2023-11-30 | — | — | WO | disclosed |
| WO-2001047873-A1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
| CN-1265095-A | Process for the preparation of N- (5-amino-2-cyano-4-fluorophenyl) sulfonamides and novel intermediates | BAYER AG (DE) | 2000-08-30 | — | — | CN | disclosed |
| CN-1265095-A | Process for the preparation of N- (5-amino-2-cyano-4-fluorophenyl) sulfonamides and novel intermediates | BAYER AG (DE) | 2000-08-30 | — | — | CN | disclosed |
| EP-1003718-A1 | METHOD FOR THE PRODUCTION OF N-(5-AMINO-2-CYANO-4-FLUORO-PHENYL)-SULPHONAMIDES AND NEW INTERMEDIATE PRODUCTS | BAYER AG (DE) | 2000-05-31 | — | — | EP | disclosed |
| EP-1003718-A1 | METHOD FOR THE PRODUCTION OF N-(5-AMINO-2-CYANO-4-FLUORO-PHENYL)-SULPHONAMIDES AND NEW INTERMEDIATE PRODUCTS | BAYER AG (DE) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999005098-A1 | METHOD FOR THE PRODUCTION OF N-(5-AMINO-2-CYANO-4-FLUORO-PHENYL)-SULPHONAMIDES AND NEW INTERMEDIATE PRODUCTS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-02-04 | — | — | WO | disclosed |
| WO-1999005098-A1 | METHOD FOR THE PRODUCTION OF N-(5-AMINO-2-CYANO-4-FLUORO-PHENYL)-SULPHONAMIDES AND NEW INTERMEDIATE PRODUCTS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | TNNT2, TNNI3, TNNC1 | KHK 2294/4885TRPV4 1604/4885CYP11B1 23/4885 |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | KHK 348/4885TRPV4 601/4885CYP11B1 203/4885 |
| US-20030040626-A1 | Method for the production of N-(5-amino-2-cyano-4-fluoro-phenyl)-sulphonamides and new intermediate products | PFAS, SRM, NISCH | KHK 560/4885TRPV4 939/4885CYP11B1 2488/4885 |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | KHK 348/4885TRPV4 601/4885CYP11B1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.